sh-Polypeptide-7 for Hair Regrowth

Evidence Review created on 08/03/2026 using AI4L / Opus 4.8

Also known as: Sh-Polypeptide-7, Somatotropin, Recombinant Human Growth Hormone, rh-GH

Motivation

sh-Polypeptide-7 is a laboratory-made copy of human growth hormone (the body’s own signal for tissue growth and repair) that has been added to a growing number of leave-on hair and scalp serums. In ingredient lists it appears under this technical name rather than as “growth hormone,” so many users do not realize what it is. The idea behind it is simple and appealing: if growth signals help skin and follicles renew themselves, applying such a signal directly to a thinning scalp might wake up sluggish hair.

Growth signals genuinely do matter for hair. The base of each follicle relies on a family of natural growth factors to keep hairs in their active growing phase, and these signals are known to weaken in pattern hair loss. This biological logic, together with the wider popularity of “growth factor” skincare, is what moved these ingredients from the research bench into over-the-counter scalp products.

This review examines what sh-Polypeptide-7 is, how it is proposed to work on hair, and what the evidence does and does not show for using it to regrow hair, including the important question of whether a large protein applied to the scalp can reach the follicle at all.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No Grokipedia article exists for sh-Polypeptide-7.

Examine

No Examine.com article exists for sh-Polypeptide-7. Examine focuses on dietary supplements and nutrients rather than topical cosmetic peptide ingredients, so this ingredient is not covered.

ConsumerLab

No ConsumerLab article exists for sh-Polypeptide-7. ConsumerLab reviews and tests ingestible supplement products, which does not include this topical cosmetic ingredient.

Systematic Reviews

No systematic reviews or meta-analyses for sh-Polypeptide-7 were found on PubMed as of August 3, 2026.

Mechanism of Action

sh-Polypeptide-7 is the cosmetic-ingredient name (under the International Nomenclature of Cosmetic Ingredients, INCI, the standardized cosmetic-ingredient naming system) for a synthetic, recombinant copy of human growth hormone (GH, also called somatotropin) — a single-chain protein of roughly 191 amino acids and about 22 kilodaltons (kDa, a unit of molecular size), produced by microbial fermentation. In hair serums it is used as a “growth factor” intended to stimulate the follicle.

Primary proposed pathway (indirect, via IGF-1): Growth hormone exerts most of its growth effects by inducing IGF-1. In the follicle, IGF-1 is secreted by dermal papilla cells (the signaling hub at the follicle base) and keeps hairs in the active growing (anagen) phase — it stimulates keratinocyte proliferation, prevents the programmed cell death that ends the growing phase, and boosts vascular endothelial growth factor (VEGF, a signal that promotes new blood-vessel formation) to improve blood supply. IGF-1 signals through the PI3K/Akt and MAPK/ERK cascades (internal cell-growth signaling pathways). Dermal papilla cells from balding scalp secrete less IGF-1 than those from non-balding scalp, which is the core rationale for supplying a growth signal externally (Hsieh et al., 2025).
Direct growth-hormone action is weak on isolated follicles: Growth-hormone receptors are present in skin, but in classic organ-culture work growth hormone alone did not stimulate isolated human follicle growth, whereas IGF-1 did (Philpott et al., 1994). This supports the view that any hair benefit from sh-Polypeptide-7 would be mediated largely by locally induced IGF-1 rather than by growth hormone acting directly.
Competing / limiting mechanism — skin penetration: A central uncertainty, presented here because it works against the intervention, is delivery. The outer skin barrier (stratum corneum) strongly resists passage of large, water-loving proteins, so whether an intact ~22 kDa growth-hormone molecule reaches the dermal papilla in active form after simple topical application is doubtful without penetration aids such as microneedling, or carriers such as liposomes or exosomes. If the protein does not penetrate or is degraded in the formulation, the mechanism above cannot operate regardless of its biological plausibility.
Key pharmacological properties: As a protein biologic rather than a small molecule, sh-Polypeptide-7 has no meaningful oral or transdermal systemic half-life at cosmetic use; injected recombinant growth hormone clears within roughly 20 minutes to a few hours, and topical growth factors show minimal systemic absorption because of their size. Selectivity is for the growth-hormone receptor (and, through induced IGF-1, the IGF-1 receptor). Tissue distribution after topical use is intended to be local to the scalp. Metabolism is by proteolytic breakdown from skin and tissue peptidases, not by liver cytochrome P450 enzymes (e.g., CYP3A4), so classic drug-metabolism interactions do not apply.

Historical Context & Evolution

Original intended use: Recombinant human growth hormone was developed as an injectable prescription hormone to treat growth-hormone deficiency in children and, later, in adults. It was never designed as a hair treatment, and its recognized medical uses remain systemic and hormonal.
How it came to hair and skin optimization: The link to hair emerged from human observation rather than from the cosmetic industry. Excess growth hormone (as in acromegaly) is associated with increased body hair, while growth-hormone and IGF-1 deficiency (as in Laron syndrome and after pituitary surgery) is associated with sparse hair and poor response to standard hair drugs (Trüeb, 2018). These findings identified the growth-hormone/IGF-1 axis as a genuine regulator of the human hair cycle.
Translation into cosmetics: During the 2000s and 2010s, the skincare industry began formulating recombinant growth factors — epidermal growth factor, fibroblast growth factors, IGF-1, and VEGF — into topical skin-rejuvenation products, and then extended the concept to scalp and hair serums. The INCI “sh-“ nomenclature (“synthetic human”) was created to label these recombinant growth-factor ingredients, with sh-Polypeptide-7 assigned to the growth-hormone/somatotropin sequence.
Current standing (not settled): The biological rationale is well documented, but direct clinical testing of topical growth-hormone for hair is essentially absent, and the delivery question remains unresolved. The historical evidence for the growth-hormone/IGF-1 role in hair should not be dismissed as disproven; rather, it is genuine biology whose translation into an effective topical product has not yet been demonstrated either way.

Expected Benefits

The benefits below are framed for a proactive, risk-aware reader considering sh-Polypeptide-7 as an optional addition to a hair-regrowth routine. Because no controlled human trial has tested this specific ingredient for hair, most benefits rest on mechanism and on indirect evidence from related growth factors; the grading reflects this honestly.

Low 🟩

Adjunctive Support Within Multi–Growth-Factor Scalp Serums

sh-Polypeptide-7 is usually one component of serums that combine several growth factors (often IGF-1-, VEGF-, and keratinocyte-growth-factor-class signals). Small, mostly industry-run studies of such growth-factor cocktails report modest improvements in hair density and thickness, and the shared biology is plausible. This is graded Low, not higher, because the signal comes from small studies of mixtures rather than from the isolated ingredient, and because the individual contribution of sh-Polypeptide-7 has never been separated out.

Magnitude: Not quantified in available studies.

Speculative 🟨

Prolongation of the Growing (Anagen) Phase

The best-supported theoretical benefit is extension of the active growing phase. Growth hormone raises local IGF-1, which keeps follicle cells dividing and blocks the cell death that ends anagen, and could in principle shift more follicles into and hold them in the growing phase. The basis is mechanistic and drawn from IGF-1 biology and animal models; no controlled human study confirms this effect for topical sh-Polypeptide-7.

Partial Reversal of Follicle Miniaturization

In pattern hair loss, follicles progressively shrink and produce finer hairs, and dermal papilla cells in balding scalp make less IGF-1. Restoring a growth signal is proposed to help counter this miniaturization and thicken hair caliber. This remains speculative: it is inferred from the association between low follicular IGF-1 and balding, not from demonstrated regrowth with this ingredient.

Improved Perifollicular Blood Supply (Angiogenesis)

By raising VEGF, IGF-1 signaling can promote new small blood vessels around the follicle, improving oxygen and nutrient delivery. Better perifollicular circulation is one of the ways minoxidil is thought to help, so an angiogenic effect is a plausible shared route to benefit. Evidence for sh-Polypeptide-7 specifically is mechanistic only, with no anecdotal or controlled human hair data isolating this pathway.

Benefit-Modifying Factors

Degree of miniaturization at baseline: Follicles that are thinning but still active are the most plausible responders; long-dormant or scarred follicles are unlikely to benefit from any growth signal.
Baseline follicular IGF-1 and nutrient status: People whose hair loss is driven partly by low growth-factor signaling, iron deficiency, low vitamin D, or thyroid imbalance may see more apparent benefit once those deficits are also corrected; a growth-factor serum cannot compensate for an untreated deficiency.
Genetic androgen sensitivity: In pattern hair loss, follicle sensitivity to dihydrotestosterone (DHT, a potent form of testosterone that shrinks susceptible follicles) — influenced by androgen-receptor and 5-alpha-reductase genetics — sets a ceiling on how much any non-anti-androgen approach can achieve.
Sex-based differences: Female-pattern loss involves diffuse thinning and different hormonal drivers than male-pattern loss, so the pattern, expectations, and realistic ceiling of benefit differ between men and women.
Age: Older individuals and those with long-standing thinning tend to have more miniaturized, less responsive follicles, so benefit is generally greater at the earlier, younger end of the target range.

Potential Risks & Side Effects

The risks below are framed for an informed reader. For a topically applied protein with poor skin penetration and negligible expected systemic absorption, the realistic risks are local and low; the more serious concerns are theoretical and hinge on whether the growth factor is absorbed at all.

Low 🟥

Application-Site Irritation and Contact Dermatitis

The most realistic adverse effect is local: itching, redness, dryness, or occasionally a contact-dermatitis reaction at the scalp, driven more often by other serum components (preservatives, solvents, fragrances) than by the growth factor itself. Reactions are typically mild and reversible on stopping. Risk rises when the serum is combined with irritating actives or with microneedling that breaks the skin barrier.

Magnitude: Not quantified for sh-Polypeptide-7; comparable topical peptide and growth-factor scalp serums report only mild, transient application-site reactions in a small minority of users.

Speculative 🟨

Theoretical Stimulation of Abnormal or Pre-Cancerous Cells

Growth hormone and IGF-1 are mitogens (they promote cell division), which raises a theoretical concern that applying them to the scalp could stimulate abnormal or pre-cancerous skin cells, particularly if delivery is enhanced by microneedling. This is speculative: there is no evidence that cosmetic topical use drives skin cancer, and penetration is likely low, but the concern is biologically coherent enough to warrant caution in people with a history of scalp skin cancer.

Effects of Unintended Systemic Absorption

If meaningful amounts were absorbed (not expected from intact-skin cosmetic use, but conceivable with damaged skin or aggressive microneedling), growth-hormone/IGF-1 excess is associated with fluid retention, joint aches, insulin resistance, and, over the long term, acromegaly-type changes and cancer-risk concerns. This is speculative for a topical product and is included only to bound the theoretical downside of enhanced delivery.

Immune Response to a Recombinant Protein

As a bacterially produced recombinant protein, sh-Polypeptide-7 could in principle provoke a local immune or allergic response, and residual bacterial components (endotoxin) from manufacturing could contribute to irritation. This has not been characterized for cosmetic use and is raised as an unstudied, isolated-report-level possibility rather than an established risk.

Risk-Modifying Factors

History of hormone-sensitive or growth-factor-responsive cancer: A personal history of scalp skin cancer, or of active hormone-sensitive cancers (e.g., breast or prostate), amplifies the theoretical growth-stimulation concern, especially if microneedling is used to enhance delivery.
Broken or inflamed scalp skin: Active dermatitis, open wounds, folliculitis, or recent aggressive procedures increase both irritation risk and the (small) chance of systemic absorption, because the skin barrier is compromised.
Sex and reproductive status: Pregnancy and breastfeeding are a modifying factor by precaution — growth-factor signaling in these states is unstudied for topical use, so avoidance is prudent rather than evidence-based.
Baseline metabolic status: People with insulin resistance or a strong family history of hormone-sensitive cancer may reasonably weight the theoretical absorption concern more heavily, even though topical exposure is expected to be negligible.
Age: Older skin can be more prone to irritation and slower to heal after microneedling-enhanced application, modestly increasing local-reaction risk.

Key Interactions & Contraindications

Prescription drug interactions: Because sh-Polypeptide-7 is a large protein with negligible systemic absorption, classic systemic drug interactions are not expected. The relevant interactions are intentional and additive: combining it with prescription hair therapies — 5-alpha-reductase inhibitors (finasteride, dutasteride) or minoxidil (topical or oral) — is complementary. Severity: monitor; consequence: potential additive benefit, not harm. Concurrent prescription systemic growth hormone would be an additive growth-factor signal — caution, given the theoretical concerns above.
Over-the-counter medication interactions: Topical actives applied to the same scalp — retinoids (tretinoin, adapalene), alpha-hydroxy acids, or benzoyl peroxide — can degrade the growth factor or increase penetration and irritation. Severity: caution; consequence: increased local irritation. Mitigation: separate applications by at least 12 hours.
Supplement interactions: No pharmacokinetic supplement interactions are expected. Layering other topical growth-factor or peptide products (copper peptides such as GHK-Cu, biotinoyl tripeptide) is additive by intent.
Additive-effect topicals to account for: Other follicle-stimulating topicals — minoxidil, caffeine, rosemary oil, and peptide serums — push in the same direction (more growth signaling and perfusion), so stacking several raises both the chance of benefit and the chance of scalp irritation and should be introduced one at a time.
Populations who should avoid it: Pregnant or breastfeeding individuals (caution/avoid — unstudied). People with active or recent (within ~5 years) hormone-sensitive cancer, or any active skin cancer on the scalp, should treat this as a relative contraindication, particularly with microneedling-enhanced delivery. People with active scalp infection, open wounds, or inflammatory scalp disease should not apply it to affected skin.
Mitigating actions: Where combined with microneedling, keep needle depth shallow (≤0.5 mm) or defer entirely in higher-risk individuals; where combined with irritating actives, stagger timing and reduce frequency.

Risk Mitigation Strategies

Patch test before scalp use: Apply a small amount to the inner forearm for 48 hours before first scalp application to detect allergic or irritant contact dermatitis before treating the whole scalp.
Apply only to intact skin: Avoid broken, inflamed, or infected scalp; treating only healthy skin minimizes both local reactions and any chance of systemic absorption of the growth factor.
Limit penetration enhancement in higher-risk users: If pairing with microneedling, keep depth at ≤0.5 mm, no more than once weekly, and skip microneedling entirely in anyone with a history of scalp skin cancer — this directly reduces the theoretical growth-factor stimulation concern.
Introduce one active at a time and stagger irritants: Add sh-Polypeptide-7 alone for 2–4 weeks before stacking, and separate it from retinoids or acid exfoliants by at least 12 hours, to prevent compounding scalp irritation.
Choose verified, well-handled product: Select serums that disclose the ingredient, state a concentration, provide third-party testing or a certificate of analysis, and specify cold-chain or refrigeration — this mitigates the “inactive or degraded product” failure that wastes months of use.
Defer during pregnancy and breastfeeding: Postpone use in these states, mitigating the unknown (though likely low) reproductive risk of applying a growth signal.

Therapeutic Protocol

There is no standardized medical protocol for sh-Polypeptide-7, because it is a cosmetic ingredient rather than an approved hair drug. The following reflects how growth-factor scalp serums are typically used by aesthetic-dermatology practitioners and product developers, presented without treating any one approach as definitive.

Core application: Apply a growth-factor serum containing sh-Polypeptide-7 to a clean, dry scalp, focusing on thinning areas, once or twice daily as a leave-on, per the manufacturer’s instructions.
Competing delivery approaches: Three main strategies coexist without a clear default — (1) serum applied alone; (2) serum applied together with weekly at-home or in-office microneedling to overcome the skin barrier; and (3) in-office growth-factor or platelet-rich-plasma mesotherapy where factors are delivered into the scalp. The microneedling-assisted approach is the one most often promoted by clinics precisely because a large protein penetrates intact skin poorly.
Positioning as an adjunct: Leading practitioners generally frame growth-factor serums as an add-on to evidence-based therapies (minoxidil, finasteride), not as a standalone replacement for them.
Best time of day: No circadian timing requirement exists; consistency matters more than clock time, and an evening routine is common so the serum is not disturbed by daytime styling.
Half-life and reapplication: As a topically applied protein it has no meaningful systemic half-life; locally it is broken down by skin peptidases within hours, which is why daily (or twice-daily) reapplication is used rather than intermittent dosing.
Single versus split application: Once- or twice-daily use is typical; twice daily is favored when the goal is steadier local exposure.
Genetic factors: Androgen-receptor sensitivity and 5-alpha-reductase activity govern pattern-hair-loss severity and thus the realistic ceiling of benefit; no validated pharmacogenetic marker predicts response to sh-Polypeptide-7 itself.
Sex-based factors: Expectations and patterns differ between male- and female-pattern loss, and use is deferred in pregnancy and breastfeeding.
Age-related factors: Older, long-miniaturized follicles respond less, so earlier initiation within the target range is more likely to help.
Baseline biomarkers: Correct iron (ferritin), vitamin D, and thyroid abnormalities before or alongside use, since these commonly limit any hair-regrowth response.
Pre-existing conditions: Scarring alopecia will not respond, and active scalp inflammation should be treated first.

Discontinuation & Cycling

Lifelong versus short-term use: Like other hair treatments, any benefit is maintenance-dependent rather than curative; sustained, continuous use would be required to maintain an effect, and gains would be expected to fade after stopping.
Withdrawal effects: None are expected pharmacologically — there is no dependence or rebound from a topical growth factor; discontinuation simply removes the added signal.
Tapering: No taper is needed; the product can be stopped abruptly without a weaning schedule.
Cycling: There is no evidence that cycling on and off improves or preserves efficacy; continuous use is the norm, and theoretical receptor down-regulation from constant exposure has not been demonstrated for this ingredient.

Sourcing and Quality

Recombinant-protein stability: Growth factors are fragile and lose activity with heat, time, and unsuitable pH; prefer formulations that address stability through encapsulation, appropriate buffering, refrigeration or cold-chain handling, and a clear, near-term expiration date.
What to look for: Confirm the ingredient is listed by its INCI name (sh-Polypeptide-7), that a concentration is stated, and that the maker provides third-party testing, a certificate of analysis, and good-manufacturing-practice sourcing; because the protein is produced in bacteria, endotoxin (bacterial-contaminant) testing is a meaningful quality marker.
Reputable sources: Favor established cosmeceutical and growth-factor serum brands with published testing over anonymous marketplace sellers; be wary of products marketed simply as “HGH for hair.”
Distinguish from injectable growth hormone: A topical cosmetic containing sh-Polypeptide-7 is not the same as pharmaceutical injectable human growth hormone; the latter is a prescription drug, and non-medical injectable use for cosmetic purposes is both riskier and, in many places, illegal.

Practical Considerations

Time to effect: Hair cycles slowly; at least 3–6 months of consistent daily use is needed before judging any effect, and roughly 12 months for a fair assessment — the same patience required of all hair treatments.
Common pitfalls: Expecting drug-level regrowth from a cosmetic; using the serum on intact skin with no penetration strategy and assuming the protein reaches the follicle; abandoning proven therapies (minoxidil, finasteride) in favor of it; buying degraded or unverified product; and confusing a topical cosmetic with systemic growth hormone.
Regulatory status: sh-Polypeptide-7 is an INCI-listed cosmetic ingredient sold in leave-on products; it is not an FDA-approved (Food and Drug Administration-approved) drug for hair loss, and marketing claims are cosmetic rather than therapeutic. Injectable recombinant growth hormone, by contrast, is a controlled prescription drug whose cosmetic or rejuvenation use is legally restricted.
Cost and accessibility: Growth-factor scalp serums are relatively expensive (commonly $50–200+ per bottle) and represent a recurring, out-of-pocket cost that is not reimbursed, which is a meaningful consideration given the uncertain benefit.

Interaction with Foundational Habits

Sleep: Direction — indirect; the topical does not meaningfully change body-wide hormone levels, but the body’s own growth-hormone release peaks during deep sleep, so poor sleep lowers the endogenous growth-factor signaling that supports follicles. Practical point: prioritizing consistent, sufficient sleep supports the same axis the serum targets, and an evening application fits naturally into a wind-down routine.
Nutrition: Direction — indirect and potentiating of the underlying axis; adequate protein, total calories, iron, zinc, and vitamin D are needed for healthy IGF-1 signaling and follicle function, whereas very-low-calorie or low-protein diets suppress IGF-1 and trigger shedding. Practical point: a growth-factor serum cannot offset a nutritional deficiency, so correct diet and iron status first.
Exercise: Direction — indirect; resistance and higher-intensity exercise transiently raise systemic growth hormone and IGF-1 and improve scalp perfusion, complementing the intended local effect. Practical point: apply the serum after washing rather than onto a sweaty scalp, since sweat and occlusion can worsen irritation.
Stress management: Direction — indirect; chronic stress and elevated cortisol can push follicles into shedding and blunt anabolic growth-factor signaling, working against the serum’s aim. Practical point: stress-reduction practices support hair broadly but do not change the serum’s local pharmacology.

Monitoring Protocol & Defining Success

Monitoring for a cosmetic hair intervention is mainly visual and functional, supported by a baseline blood panel to rule out common, correctable drivers of hair loss that would otherwise mask or limit any response.

Baseline assessment should be established before starting: standardized scalp photographs under consistent lighting, a hair-pull test, optional trichoscopy (magnified scalp imaging), and the baseline labs below to identify contributors to shedding.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Ferritin (iron stores)	40–70 ng/mL	Low iron stores are a common, reversible cause of hair shedding	Conventional “normal” starts ~15–30 ng/mL, too low for hair; ferritin rises with inflammation, so pair with a C-reactive protein (CRP, a general inflammation marker)
Vitamin D (25-hydroxy)	40–60 ng/mL	Deficiency is linked to disrupted hair cycling	Conventional sufficiency is set lower (≥20–30 ng/mL); fasting not required
TSH (thyroid-stimulating hormone)	0.5–2.0 mIU/L	Thyroid over- or under-activity causes diffuse hair loss	Conventional upper limit ~4.0–4.5; pair with free T4/free T3; a morning draw is preferred
Serum IGF-1	Mid-range for age and sex	Reflects the growth-hormone/IGF-1 axis relevant to follicle signaling	Not routinely required for cosmetic topical use; interpret against age-adjusted reference; fasting not required

Ongoing monitoring should follow a set cadence: repeat standardized photographs and, if available, trichoscopy at 12 weeks and 24 weeks, then every 6 months, since visible change is slow. Recheck any abnormal baseline lab (ferritin, vitamin D, thyroid) after it has been addressed.

Qualitative markers of progress to track are:

Daily hair shedding (hairs on the pillow, in the shower, or on the brush) trending down.
Part width and overall density appearing fuller in consistent photos.
Individual hair caliber (finer versus thicker regrowth) at the hairline and crown.
Scalp comfort — absence of persistent itching, redness, or flaking from the product.

Emerging Research

Framed for a reader weighing whether to wait for better evidence, the active research directions below include both signals that could strengthen and signals that already weaken the case for topical growth factors in hair.

Peptide/growth-factor serum versus standard therapy: A randomized trial is comparing a peptide-factor hair serum against topical 2% minoxidil for androgenetic alopecia (NCT07536100), enrolling about 80 participants at the Institute of Dermatology, Thailand — a rare head-to-head design that could show whether growth-factor serums match an established therapy.
Dedicated growth-factor product for pattern loss: An early-phase (Phase 1/2) study of a growth-factor-based product (XVIE) for androgenetic alopecia is planned (NCT07482423, ~30 participants), alongside a pilot of the same product delivered by microneedling in women with thinning hair (NCT07221773) — directly testing the delivery question central to this ingredient.
Growth-factor complex, completed: A Phase 1 study of a hair-stimulating growth-factor complex (HST-001) in male pattern hair loss has completed (NCT04435847, ~36 participants), part of the small body of growth-factor-cocktail work that underlies current serums.
A cautionary negative signal: A single-growth-factor topical (keratinocyte-growth-factor hair serum) failed to prevent chemotherapy-induced hair loss in a completed trial (Mann et al., 2026; NCT04554732), consistent with the concern that a topically applied growth factor may not reach the follicle in sufficient amount.
Delivery technology as the deciding variable: Reviews of topical IGF-1 argue that liposomal gels, exosome carriers, and microneedle patches — not the growth factor alone — will determine whether these proteins reach the dermal papilla (Hsieh et al., 2025); progress here could either validate or retire the topical-growth-hormone concept.
The key missing study: No published randomized trial isolates sh-Polypeptide-7 against a vehicle control for hair regrowth; such a trial is the single most important piece of evidence needed to move any benefit above speculative.

Conclusion

sh-Polypeptide-7 is a cosmetic-serum ingredient that is, in plain terms, a lab-made copy of human growth hormone applied to the scalp as a “growth factor.” Its appeal rests on solid biology: the growth-hormone and insulin-like growth factor system genuinely helps keep hairs in their growing phase, and this signaling is known to weaken in pattern hair loss. That rationale is the strongest part of the case.

The evidence that applying it to the scalp actually regrows hair, however, is very thin. No controlled human study has tested this specific ingredient for hair, so the expected benefits remain speculative and rest on mechanism and on small studies of growth-factor mixtures. A major open question is whether such a large protein can even pass through the skin to reach the follicle, and one related product failed when tested for a different form of hair loss.

The safety picture for normal topical use appears mild, with local irritation the most realistic issue; more serious concerns are theoretical and depend on absorption that is probably minimal. Overall, sh-Polypeptide-7 is a biologically reasonable but largely unproven option whose real-world value is uncertain and whose careful, honest reading is that promise currently outruns evidence.

Top - Benefits - Risks - Protocol

sh-Polypeptide-7 for Hair Regrowth

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Low 🟩

Adjunctive Support Within Multi–Growth-Factor Scalp Serums

Speculative 🟨

Prolongation of the Growing (Anagen) Phase

Partial Reversal of Follicle Miniaturization

Improved Perifollicular Blood Supply (Angiogenesis)

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Application-Site Irritation and Contact Dermatitis

Speculative 🟨

Theoretical Stimulation of Abnormal or Pre-Cancerous Cells

Effects of Unintended Systemic Absorption

Immune Response to a Recombinant Protein

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion